Somatostatin receptor type 2 and thyroid-stimulating hormone receptor expression in oncocytic thyroid neoplasms: Implications for prognosis and treatment
A Gillis, R Zheng-Pywell, C McLeod, D Wang, JM Ness… - Modern Pathology, 2023 - Elsevier
Abstract Somatostatin receptor type 2 (SSTR2) and thyroid-stimulating hormone receptor
(TSHR) display variable expression in primary thyroid tumors and have been implicated as …
(TSHR) display variable expression in primary thyroid tumors and have been implicated as …
[HTML][HTML] Hurthle cell thyroid carcinoma
MM Fariduddin, W Syed - StatPearls [Internet], 2023 - ncbi.nlm.nih.gov
Objectives: Describe the pathophysiology of Hurthle cell thyroid carcinomas. Review the
histological characteristics of Hurthle cell carcinomas of the thyroid. Summarize …
histological characteristics of Hurthle cell carcinomas of the thyroid. Summarize …
Hurthle cell carcinoma: a rare variant of thyroid malignancy–a case report
Y Adhikari, A Marasini, N Adhikari… - Annals of Medicine …, 2023 - journals.lww.com
Conclusion: This case highlights on rarity of disease, presentation, and availability of
treatment modality. Introduction Highlights Rare variant of follicular thyroid malignancy …
treatment modality. Introduction Highlights Rare variant of follicular thyroid malignancy …